REGENXBIO Inc. 2025 Annual Report: Investor Highlights and Key Shareholder Information

Overview

REGENXBIO Inc. (Nasdaq: RGNX) has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report contains important information for shareholders, including regulatory compliance, corporate structure, and forward-looking statements.

Key Points from the Annual Report

• Regulatory Status: REGENXBIO is a well-known seasoned issuer, confirming its continual compliance with SEC filing requirements. The company is not a shell company and has submitted all required reports and interactive data files, maintaining transparency and regulatory integrity.
• Stock Information: The company’s common stock, with par value \$0.0001 per share, is listed on The Nasdaq Global Select Market under the trading symbol “RGNX”. As of June 30, 2025, the aggregate market value of shares held by non-affiliates was substantial, with 51,184,000 shares issued and outstanding.
• Corporate Structure: REGENXBIO Inc. operates as a consolidated entity alongside its subsidiaries, headquartered at 9804 Medical Center Drive, Rockville, MD.
• SEC Filings and Compliance: The company confirmed it is an accelerated filer and a smaller reporting company but not an emerging growth company. There were no restatements or corrections to previously issued financial statements, nor any recovery analysis related to incentive-based compensation.
• Forward-Looking Statements: Management has highlighted several risk factors and operational priorities that could materially affect future performance:
  • Timely development and launch of new products.
  • Scope, progress, and costs of developing and commercializing product candidates.
  • Growth strategies and expectations regarding competition.
  • Anticipated trends and challenges in the market.
  • Ability to attract and retain key personnel.
  • Market size and acceptance of new products.
  • Expense and revenue projections, need for additional financing, and outcome of legal proceedings.
  • Regulatory developments in the U.S. and abroad, including potential government tariffs.
  • Ability to continue as a going concern.
  • Potential changes in the financial markets and banking system affecting financing options and cash resources.
• Industry and Market Data: Internal estimates and third-party industry data have been used to inform management’s outlook. While considered reliable, these estimates are subject to change and uncertainty.
• Documents Incorporated by Reference: Portions of the company’s definitive proxy statement for the 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of the Form 10-K, which may include additional details on governance and compensation.
• Trademarks: REGENXBIO holds trademarks such as AAVIATE, AFFINITY BEYOND, ALTITUDE, ASCENT, ATMOSPHERE, CAMPSIITE, NAV, NAVXpress, NAVXcell, and others, reinforcing its brand presence.

Potentially Price-Sensitive Information

• Forward-Looking Risks: The extensive list of risk factors and uncertainties, including product launch timelines, regulatory changes, market acceptance, and financing needs, could significantly impact share price depending on developments in these areas.
• Financial Health: Management notes its ability to continue as a going concern as a key risk, suggesting investors should monitor liquidity and cash flow closely.
• Regulatory and Legal Developments: Any significant regulatory changes or legal outcomes could affect operations and share value.
• No Corrections or Restatements: The absence of restatements or corrections to financial statements provides reassurance regarding the reliability of past financial reporting.

Shareholder Actions and Upcoming Events

• Annual Meeting: Shareholders should anticipate additional information in the upcoming proxy statement for the 2026 Annual Meeting, which will address director elections, executive compensation, and governance matters.
• Monitoring Risk Factors: Investors are encouraged to review the “Risk Factors” section and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for more granular details on operational and financial risks.
• Brand and Market Position: The company’s strong portfolio of trademarks and reliance on proprietary technology are central to its competitive advantage.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The information has been compiled based on the latest available annual report and may be subject to change. Investors should conduct their own research and consult with financial advisors before making investment decisions. REGENXBIO Inc. disclaims any duty to update forward-looking statements except as required by law.

View REGENXBIO Inc. Historical chart here